Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Circulation Research|October 18, 2008
Lats2 is a negative regulator of myocyte size in the heartYutaka Matsui, Noritsugu Nakano, Dan Shao, et al.
Biology of Reproduction|October 17, 2008
Characterization of antiestrogenic activity of the Chinese herb, prunella vulgaris, using in vitro and in vivo (Mouse Xenograft) modelsNancy H Collins, Elizabeth C Lessey, Carolyn D DuSell, et al.
Cancer Immunology, Immunotherapy : CII|February 20, 2016
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2Julia M Greene, Erika J Schneble, Doreen O Jackson, et al.
The Journal of Clinical Investigation|November 9, 2005
Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic micePeiyong Zhai, Mitsutaka Yamamoto, Jonathan Galeotti, et al.
Vaccine|May 5, 2018
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumorsGarth S Herbert, Timothy J Vreeland, Guy T Clifton, et al.
Immunotherapy|February 24, 2018
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccineMark O Hardin, Timothy J Vreeland, Guy T Clifton, et al.
Cancer Immunology, Immunotherapy : CII|August 31, 2022
Divergent clinical outcomes in a phase 2B trial of the TLPLDC vaccine in preventing melanoma recurrence and the impact of dendritic cell collection methodology: a randomized clinical trialAlexandra M Adams, Elizabeth L Carpenter, Guy T Clifton, et al.
Journal for Immunotherapy of Cancer|August 3, 2023
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysisElizabeth Lee Carpenter, Spencer Van Decar, Alexandra M Adams, et al.
Cancer Treatment and Research Communications|September 21, 2024
Tumor lysate particle only vaccine (TLPO) vs. Tumor lysate particle-loaded, dendritic cell vaccine (TLPLDC) to prevent recurrence in resected stage III/IV melanoma patients: Results of a phase I/IIa trialSpencer G Van Decar, Elizabeth L Carpenter, Alexandra M Adams, et al.
Pageof 5